ACAlfredo Cordova

Alfredo Cordova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alfredo Cordova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Consensus Recommendations for Intact Fish Skin Graft in the Management of Burn Injury

    by Rajiv Sood, Alfredo Cordova, John C. Lantis Ii, Marcus Yarbrough, Ariel Aballay, Carrie McGroarty, Ram Velamuri

    Background: Intact fish skin graft (IFSG) derived from North Atlantic cod emerged as a treatment for burns in 2019. This consensus paper presents the best to date evidence and experience-based recommendations from eight U.S. burn care experts regarding optimal use of IFSG across different burn depths and wound types. Methods: Eight U.S. burn specialists with routine IFSG experience conducted a two cycle modified Nominal Focus Group. A systematic literature search (through April 2024) was conducted, followed by informed discussion, and the generation of consensus statements. Consensus was defined as ≥80 % agreement on a 5 point Likert scale. Results: Full or strong consensus (≥80 %) was reached on 12/15 statements. IFSG is recommended for: mid-dermal & deep-dermal partial-thickness burns (as definitive treatment), full thickness traumatic & burn wounds (in a 2-stage procedure before split-thickness skin graft). IFSG is not routinely recommended for purely epidermal burns. Based on recommendations from panelists, IFSG should be applied immediately after thorough debridement except in traumatic wounds when IFSG application should be delayed until clear demarcation and resolution of any infection. Reapplication is rarely required and, if needed, should occur 6–10 days after the initial graft. For wounds >100 cm², negative pressure wound therapy (NPWT) is the preferred bolster. The panel agreed IFSG accelerates readiness for STSG, decreases procedural pain, and can reduce nursing burden and overall cost of care. Recommendations: Clinicians should reserve IFSG for deep-dermal or full thickness burns and traumatic wounds and should pair IFSG with NPWT for large areas. IFSG is not needed in superficial burns that heal adequately with standard care. Prospective trials in deep-dermal partial thickness and full thickness burns remain a priority.

  • Open Access

    Maximizing wound coverage in full-thickness skin defects: A randomized-controlled trial of autologous skin cell suspension and widely meshed autograft versus standard autografting

    by Sharon Henry, Steven Mapula, Mark Grevious, Kevin N. Foster, Herbert Phelan, Jeffrey Shupp, Rodney Chan, David Harrington, Neil Mashruwala, David A. Brown, et al.

    BACKGROUND: Traumatic insults, infection, and surgical procedures can leave skin defects that are not amenable to primary closure. Split-thickness skin grafting (STSG) is frequently used to achieve closure of these wounds. Although effective, STSG can be associated with donor site morbidity, compounding the burden of illness in patients undergoing soft tissue reconstruction procedures. With an expansion ratio of 1:80, autologous skin cell suspension (ASCS) has been demonstrated to significantly decrease donor skin requirements compared with traditional STSG in burn injuries. We hypothesized that the clinical performance of ASCS would be similar for soft tissue reconstruction of nonburn wounds. METHODS: A multicenter, within-patient, evaluator-blinded, randomized-controlled trial was conducted of 65 patients with acute, nonthermal, full-thickness skin defects requiring autografting. For each patient, two treatment areas were randomly assigned to concurrently receive a predefined standard-of-care meshed STSG (control) or ASCS + more widely meshed STSG (ASCS+STSG). Coprimary endpoints were noninferiority of ASCS+STSG for complete treatment area closure by Week 8, and superiority for relative reduction in donor skin area. RESULTS: At 8 weeks, complete closure was observed for 58% of control areas compared with 65% of ASCS+STSG areas (p = 0.005), establishing noninferiority of ASCS+STSG. On average, 27.4% less donor skin was required with ASCS+ STSG, establishing superiority over control (p < 0.001). Clinical healing (≥95% reepithelialization) was achieved in 87% and 85% of Control and ASCS+STSG areas, respectively, at 8 weeks. The treatment approaches had similar long-term scarring outcomes and safety profiles, with no unanticipated events and no serious ASCS device-related events. CONCLUSION: ASCS+STSG represents a clinically effective and safe solution to reduce the amount of skin required to achieve definitive closure of full-thickness defects without compromising healing, scarring, or safety outcomes. This can lead to reduced donor site morbidity and potentially decreased cost associated with patient care. Clincaltrials.gov identifier: NCT04091672 LEVEL OF EVIDENCE: Therapeutic/Care Management; Level I.